INTRODUCTION
Obesity and the prevalence of metabolic syndrome are currently increasing [1] . Non-alcoholic fatty liver disease (NAFLD) is a liver metabolic syndrome in which excess triglycerides (TGs) are stored in the liver despite a lack of excess alcohol consumption [2] . The prevalence of NAFLD in developed countries is estimated to be 3-5% [3] . Approximately 10% of NAFLD cases are considered non-alcoholic steatohepatitis (NASH), which can progress to potentially fatal cirrhosis and liver cancer [4] [5] [6] [7] . The increased prevalence of NAFLD is a serious health problem in many countries including Japan [8, 9] . NASH has recently attracted attention as a cause of progressive chronic liver disease of non-viral etiology; thus, distinguishing severe fibrosis from non-severe fibrosis in NASH is indispensable [10] . Liver biopsy and histological examination have been essential for determining liver fibrosis progression [2, [11] [12] [13] . However, liver biopsy is invasive and may pose risks including intra-abdominal bleeding and death in rare cases [14, 15] . In addition, hospitalization during liver biopsy may increase healthcare costs [16] . Therefore, liver biopsy for all NAFLD patients is unrealistic; establishing a non-invasive method to easily and accurately distinguish severe fibrosis in NASH is an urgent issue. There are three ways to non-invasively assess liver fibrosis: a combination of routine blood tests (i.e., indirect fibrosis markers); detecting fibrosis-related markers in the blood (i.e., direct fibrosis markers); or assessment of liver elasticity using vibration-controlled transient elastography, ultrasound elastography, or magnetic resonance imaging-based assessment of the liver-to-major psoas muscle intensity ratio [17] . Liver elasticity assessments can be limited because of the requirement of specific equipment.
Direct fibrosis markers widely studied for evaluating fibrosis in NAFLD include the type IV collagen 7S domain and/or hyaluronic acid (HA) [18] . In addition, serum immunoreactive collagen IV detected by one-step sandwichlinked enzyme immunoassay using two monoclonal antibodies directed to different antigenic sites (i.e., the 7S and triple-helix domains of collagen IV) that enables the detection of soluble collagen IV but not the 7S fragment has been used as a fibrosis marker for various liver diseases and chronic hepatitis C (CHC) [19] [20] [21] . Serum levels of type IV collagen 7S domain are well correlated with those of immunoreactive collagen IV, and immunoreactive collagen IV serum level is considered a marker for evaluating liver fibrosis in NAFLD [22] . However, the clinical significance of immunoreactive collagen IV has not been studied extensively. In addition, recent innovations in immune-mediated latex particle agglutination measurement techniques have enabled the easy and rapid quantification of collagen IV according to an increase of turbidity detected by an auto-analyzer.
The present study assessed serum immunoreactive collagen IV as a marker of severe fibrosis in NAFLD in comparison to other direct or indirect fibrosis markers. We also examined the significance of fibrosis markers in CHC. Finally, the usefulness of immunoreactive collagen IV for evaluating fibrosis in NAFLD was determined.
MATERIAL AND METHODS

Patients
This retrospective study included 148 NAFLD patients who had undergone liver biopsy between 2008 and 2013, and 187 CHC patients who had undergone liver biopsy between 2011 and 2013 at Jikei University Katsushika Medical Center. This study was approved by the Ethics Committees of the Jikei University School of Medicine and the Jikei University Katsushika Medical Center and adhered to the principles of the Declaration of Helsinki. Informed consent was obtained from all patients prior to participation.
The diagnosis of NAFLD was based on liver biopsies showing >5% hepatocyte steatosis as well as the exclusion of other etiologies of liver diseases, including viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, druginduced liver diseases, hemochromatosis, primary sclerosing cholangitis, Wilson's disease, α1-antitrypsin deficiency, and heavy alcohol consumption (>20 g pure alcohol per day). Chronic hepatitis C was diagnosed when the patient was positive for HCV-antibody and HCV-RNA for more than six months. The exclusion criteria were similar to those for NAFLD, i.e., other etiologies of liver diseases including NAFLD and heavy alcohol consumption. Furthermore, patients with HIV or hepatitis B virus infection, or receiving immune suppression therapy were excluded.
Demographics and laboratory data
On the day the patients underwent liver biopsy, basic laboratory data were collected from sera after at least 10 hours of fasting. Data included aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl-transpeptidase (GGT), albumin, total cholesterol (TC), TGs, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), hemoglobin (Hb), platelet count (PLT), prothrombin time (PT), collagen IV, and HA. In addition, basic demographic data including body mass index (BMI) were collected. Type 2 diabetes mellitus (T2DM) was diagnosed according to the World Health Organization diabetes diagnostic criteria [23] . All laboratory data were measured using standard techniques. The upper limit of normal AST level was set at 35 IU/L.
Measurement of serum collagen IV and HA
Serum immunoreactive collagen IV and HA were measured as direct biomarkers of liver fibrosis using same sera used to examine basic laboratory parameters. To detect collagen IV, immune-mediated agglutination of latex particles was applied using two types of monoclonal antibodies; one directed to the 7S domain of collagen IV (clone 1D6), and the other directed to the central triple-helix domain of collagen IV (clone 4H12). Thus, using a combination of these monoclonal antibodies enabled the detection of serum collagen IV but not the collagen IV 7S fragment. Briefly, 20 μL serum was diluted in 180 μL buffer solution and mixed with 90 μL latex reagent (containing latex particles fixed with monoclonal antibodies on the surface). The turbidity caused by latex particle agglutination at 37°C 80 and 320 seconds from the beginning of the reaction was assessed by an auto-analyzer (7150, Hitachi, Tokyo, Japan) at an optical density of 700 nm. The concentration of soluble collagen IV was quantified on the basis of the increase of turbidity (Panassay®IV-C [Latex], EIDIA, Tokyo, Japan).
Serum HA was measured using similar technology (Wako, Osaka, Japan). Sample serum was mixed with the solution containing HA-binding protein to form HA/HA-binding protein complexes. Then, a latex reagent with anti-HA-binding protein monoclonal antibody fixed on the surface of the latex particles was mixed with the solution, and the agglutination of latex particles was assessed according to the increase of turbidity at an optical density of 800 nm.
Calculation of FIB-4 and AST-to-platelet ratio index (APRI)
As an indirect marker of liver fibrosis, FIB-4 was calculated according to the formula given by Sterling et al. [24] : age 
Histological evaluation of liver fibrosis
As the gold standard reference of liver fibrosis, the histological degree of fibrosis (i.e., fibrosis stage) of liver biopsy specimens was evaluated by hematoxylin/eosin and Masson's trichrome staining. The severity of fibrosis in NAFLD was scored according to the histological fibrosis staging proposed by the NASH Clinical Research Network as follows: stage 0, no fibrosis; stage 1, perisinusoidal or periportal fibrosis; stage 2, perisinusoidal and portal/periportal fibrosis; stage 3, bridging fibrosis; and stage 4, cirrhosis [12] . The fibrosis stage of chronic HCV infection was clarified according to the METAVIR classification as follows: F0, no fibrosis; F1, portal fibrosis without bridges; F2, portal fibrosis with rare bridges; F3, numerous bridges without cirrhosis; and F4, cirrhosis. Severe fibrosis was defined as stage 3 or 4 in NAFLD and as F3 or F4 in CHC [26, 27] .
Statistical analysis
Categorical data are expressed as number (%), and continuous variables are expressed as median (interquartile range, Q1-Q3). To elucidate factors associated with severe fibrosis, multiple logistic regression analysis was performed using the stepwise backward elimination method. The sensitivity, specificity, and positive and negative predictive values (PPV and NPV, respectively) of collagen IV, HA, FIB-4, and APRI for the diagnosis of severe fibrosis were assessed. Optimum cutoff values were calculated to optimize sensitivity and specificity (i.e., the Youden index). Receiver-operating characteristic (ROC) curves were plotted, and the areas under the ROC curves (AUROCs) were calculated to assess the performance of each marker to distinguish severe liver fibrosis. Correlations were calculated using Spearman's rank correlation coefficient. The level of statistical significance was set at p<0.05 (two-tailed). All analyses were performed using SPSS version 22 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient᾿s characteristics
The patients' characteristics are shown in Table I . The NAFLD patients were predominantly female. BMI was higher in NAFLD patients than in CHC patients; PLT, TC, and FPG were higher in NAFLD than CHC. The prevalence of T2DM was 33.8% among NAFLD patients and only 4.6% among CHC patients. Among direct fibrosis markers, HA was higher in CHC patients than in NAFLD patients, while no significant difference was found for collagen IV. The APRI was higher in CHC patients, but FIB-4 was similar in NAFLD and CHC patients. Regarding fibrosis, 28 (18.9%) and 9 (4.8%) patients with NAFLD and CHC had no fibrosis, respectively; meanwhile, 42 (28.2%) and 48 (25.6%) had severe fibrosis, respectively.
Correlations between histological staging of liver fibrosis and fibrosis markers
Collagen IV, HA, FIB-4, and APRI were all significantly higher in severe liver fibrosis than in non-severe fibrosis in both NAFLD and CHC. In NAFLD, the fibrosis stage determined by histology was significantly correlated with collagen IV (ρ=0. (Fig. 2) . As in NAFLD, collagen IV also exhibited the second strongest correlation, although the correlation coefficient was lower.
Factors associated with severe fibrosis in NAFLD and CHC patients
A multiple logistic regression model was constructed using stepwise backward elimination that started with demographic and laboratory variables including collagen IV and HA but excluded FIB-4 and the APRI, because their values were calculated by a formula that combines demographics and/or laboratory tests. Collagen IV, PT, and FPG were significantly associated with severe fibrosis in NAFLD; meanwhile, HA, PLT, and GGT were significantly associated with severe fibrosis in CHC (Table II) . (Fig. 3) . (Fig. 4) .
To differentiate stage 0-2 from stage 3/4 fibrosis in NAFLD, a cutoff of collagen IV > 177 ng/mL gave the highest specificity and NPV, and the second-highest sensitivity and PPV. To differentiate F0-2 from F3/4 fibrosis in CHC, a cutoff value of collagen IV > 161 ng/mL gave the highest NPV but the lowest PPV among the four fibrosis markers (Table III) .
Combination of collagen IV and FIB-4 for more reliable differentiation of severe fibrosis in NAFLD and CHC
In NAFLD, if both collagen IV and FIB-4 were negative, severe fibrosis was unlikely to be present, as the NPV of either collagen IV > 177 ng/mL or FIB-4 > 2.09 was as high as 91.5% (95%CI: 88.2-94.8). However, if both markers were positive, severe fibrosis was likely to be present, as the PPV was 88.6% (95%CI: 84.2-93.0) and the specificity was 94.1% (95%CI: 91.7-96.7).
In CHC, the combination of collagen IV and FIB-4 showed a similar ability to distinguish severe fibrosis: the NPV (89.6%, 95%CI: 85.6-93.6) was high when both markers were negative, and the PPV (91.3%, 95%CI: 87.8-94.7) and specificity (95.2%, 95%CI: 93.3-97.1) were high when both markers were positive (Table IV) .
DISCUSSION
This study determined the utility of collagen IV detected by immune-mediated agglutination of latex particles using two monoclonal antibodies for evaluating severe liver fibrosis in patients with NAFLD. The major advantages of this Abbreviations: OR, odds ratio; CI, confidence interval; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; NAFLD, non-alcoholic fatty liver disease; CHC, chronic hepatitis C; HA, hyaluronic acid; APRI, aspartate aminotransferase-to-platelet ratio index. innovative method for analyzing serum collagen IV are its technical simplicity and speed. The quantity of collagen IV detected by immune-mediated agglutination of latex particles is correlated with that quantitated by the former enzyme immunoassay [19] . Besides collagen IV, HA is another widely studied and useful direct liver fibrosis marker for evaluating liver fibrosis in NAFLD [28] . Hyaluronic acid can be easily and quickly measured using similar innovative methods as those for collagen IV.
In the present study, all examined fibrosis markers were significantly correlated with liver fibrosis in both NAFLD and CHC. Multiple logistic regression analysis showed that collagen IV was associated with severe liver fibrosis in NAFLD but not in CHC patients. Furthermore, the AUROC of collagen IV in NAFLD was greater than that of HA. Therefore, collagen IV is useful as a direct marker of fibrosis for distinguishing severe fibrosis in NAFLD; however, its utility is not striking in CHC. Among indirect fibrosis markers, the utility of FIB-4 was superior to that of APRI in both NAFLD and CHC. However, as the AUROC of collagen IV was greater than that of FIB-4, collagen IV is still useful for determining fibrosis in NAFLD even after indirect fibrosis markers are considered. Furthermore, the combined evaluation of collagen IV and FIB-4 enhanced the diagnostic value of severe liver fibrosis in both NAFLD and CHC, and may therefore reduce the number of patients who require liver biopsy, to estimate severe liver fibrosis.
Collagen IV and laminin are the major components of basement membrane that increase in serum during chronic liver disease [19] . Assessment of basement membrane remodeling using monoclonal antibodies against neo-epitopes released in serum after the degradation of type IV collagen by matrix metalloproteinase has recently become possible. As novel markers of fibrosis, the serum levels of specific fragments of type IV collagen have been measured by competitive ELISAs [29] [30] [31] . These fibrosis markers are theoretically more reliable than others, because fibrosis is characterized by excessive basement membrane remodeling; furthermore, remodeling by matrix metalloproteinase generates neo-epitopes released into the circulation. Among these methods, ELISA for the neo-epitope of the 7S domain (P4NP 7S) and that of the α3 chain (C4M12a3) have been applied to evaluate liver fibrosis in animal models. However, the usefulness of these assays to investigate pathological remodeling in human chronic liver diseases including NAFLD has not been validated [29] [30] [31] . Future clinical studies are required to establish the significance of these novel fibrosis markers in NAFLD.
One limitation of this study is that we did not include elastography or other imaging modalities for liver fibrosis assessment. Although the utility of imaging systems is widely accepted, it is unrealistic to expect specific instruments for estimating liver fibrosis will be available at all medical institutions. Thus, fibrosis markers will continue to be used in general, because blood collection can be performed everywhere.
CONCLUSIONS
Our findings strongly suggest that collagen IV measured by immune-mediated agglutination using two types of monoclonal antibodies can be applied as a single marker of severe liver fibrosis in NAFLD. Combined with FIB-4, collagen IV may also be useful to accurately distinguish severe liver fibrosis in both NAFLD and CHC. 
